Division of Endocrinology and Metabolism, Department of Internal Medicine, Hitit University School of Medicine, Corum, Turkey.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.
Front Endocrinol (Lausanne). 2021 Feb 25;12:598249. doi: 10.3389/fendo.2021.598249. eCollection 2021.
Obesity has been reported as a risk factor for adverse outcomes in COVID-19. However, available studies presenting data on obesity prevalence in patients with COVID-19 have conflicting results. The objective of this systematic review and meta-analysis is to evaluate the prevalence of obesity in these patients and to stratify the estimates by illness severity.
We performed a literature search with the use of Medline/PubMed and Google Scholar database from December 1, 2019 to June 27, 2020 and systematically reviewed studies reporting the number of obese patients with real-time reverse transcriptase polymerase chain reaction (rRT-PCR)-confirmed SARS-CoV-2 infection.
Nineteen studies were identified. The pooled obesity prevalence rates were 0.32 (95% CI: 0.24-0.41) in hospitalized patients, 0.41 (95% CI: 0.36-0.45) in patients admitted to intensive care unit, 0.43 (95% CI: 0.36-0.51) in patients needing invasive mechanic ventilation (IMV), and 0.33 (95% CI: 0.26-0.41) in those who died. Obesity was associated with a higher risk for hospitalization [Odds ratio (OR): 1.3, 95% CI: 1.00-1.69; I 52%, = 0.05], ICU admission (OR: 1.51, 95% CI: 1.16-1.97; I 72%, = 0.002), and IMV requirement (OR: 1.77, 95% CI: 1.34-2.35; I 0%, < 0.001). The increase in risk of death did not reach statistical significance (OR: 1.28, 95% CI: 0.76-2.16, p = 0.35) which might be due to obesity survival paradox and/or unidentified factors.
Our data indicate that obese subjects may be at higher risk for serious illness if infected and obesity may play a role in the progression of COVID-19.
肥胖已被报道为 COVID-19 不良结局的危险因素。然而,目前有关 COVID-19 患者肥胖患病率的研究结果存在差异。本系统评价和荟萃分析的目的是评估这些患者的肥胖患病率,并按疾病严重程度对估计值进行分层。
我们使用 Medline/PubMed 和 Google Scholar 数据库进行了文献检索,检索时间为 2019 年 12 月 1 日至 2020 年 6 月 27 日,并对报告实时逆转录聚合酶链反应(rRT-PCR)确诊 SARS-CoV-2 感染的肥胖患者数量的研究进行了系统回顾。
共确定了 19 项研究。住院患者的肥胖患病率为 0.32(95%CI:0.24-0.41),入住重症监护病房的患者为 0.41(95%CI:0.36-0.45),需要有创机械通气(IMV)的患者为 0.43(95%CI:0.36-0.51),死亡患者为 0.33(95%CI:0.26-0.41)。肥胖与住院(优势比[OR]:1.3,95%CI:1.00-1.69;I 52%, = 0.05)、入住重症监护病房(OR:1.51,95%CI:1.16-1.97;I 72%, = 0.002)和需要 IMV(OR:1.77,95%CI:1.34-2.35;I 0%,<0.001)的风险增加相关。死亡风险的增加没有达到统计学意义(OR:1.28,95%CI:0.76-2.16,p = 0.35),这可能是由于肥胖生存悖论和/或未识别的因素所致。
我们的数据表明,如果感染,肥胖患者可能患重病的风险更高,肥胖可能在 COVID-19 的进展中发挥作用。